Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer.

ABSTRACT:

Introduction

Homologous recombination deficiency (HRD) testing is used to determine the appropriateness of poly ADP-ribose polymerase inhibitors for patients with epithelial ovarian cancer and no germline/somatic BRCA1/2 alterations. Myriad MyChoice CDx reports a genomic instability score (GIS) to quantify the level of HRD, with a positive score defined as ≥42. The authors sought to define factors associated with obtaining an inconclusive HRD test result.

Methods

GIS was retrieved for patients at their institution with epithelial ovarian cancer without germline/somatic BRCA1/2 deleterious alterations who underwent HRD testing from April 2020-August 2023. Clinical data were abstracted from the medical record.

Results

Of 477 HRD test results identified, 57 (12%) were in

SUBMITTER: Sullivan MW 

PROVIDER: S-EPMC11695162 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature